High tumoral PD-L1 expression and low PD-1⁺ or CD8⁺ tumor-infiltrating lymphocytes are predictive of a poor prognosis in primary diffuse large B-cell lymphoma of the central nervous system

Sehui Kimᵃᵇ, Soo Jeong Namᶜ, Changhee Parkᵈ, Dohee Kwonɵᵃᵇ, Jeemin Yim⁵, Seung Geun Song⁶, Chan-Young Ock⁶, Young A Kim⁶, Sung Hye Parkᵃ, Tae Min Kimᵇᵈ, and Yoon Kyoung Jeonᵃᵇ

We investigated the clinicopathological role of the PD-1/PD-L1 pathway in primary diffuse large B-cell lymphoma of the central nervous system (PCNS-DLBCL) arising in the immune-privileged site. PD-L1 immunostaining of ≥30% of tumor cells was defined as tPD-L1⁺, and PD-L1 immunostaining of ≥30% of total cellularity, including tumor and non-tumoral cells, as tmPD-L1⁺. PD-1⁺ and CD8⁺ tumor-infiltrating lymphocytes (TILs) were enumerated. Thirty-five cases (35.7%) were tPD-L1⁺ and 47 cases (48%) were tmPD-L1⁺. The number of TILs was greater in tmPD-L1⁺ cases than in tmPD-L1− cases (CD8⁺, P= .050; PD-1⁺, P=.019). tPD-L1⁺ and tmPD-L1⁺ cases tended to have a poor performance status. In contrast, the numbers of CD8⁺ and PD-1⁺ TILs tended to be higher in patients with a good performance status and MYC/BCL2 negativity. Patients with tPD-L1⁺ had a worse overall survival (P= .026), and those with increased CD8⁺ or PD-1⁺ TILs tended to have a better overall survival (P= .081 and 0.044, respectively). Tumoral PD-L1 expression and the number of PD-1⁺ TILs were independent prognostic factors. tPD-L1⁺ patients with a small number of CD8⁺ or PD-1⁺ TILs had the worst prognosis, and tPD-L1− patients with a large number of CD8⁺ or PD-1⁺ TILs had the best prognosis. In validation group, increased CD8⁺ or PD-1⁺ TILs were significantly associated with a prolonged survival, but PD-L1 had no prognostic significance. In conclusion, PD-L1 is frequently expressed in tumor cells and the immune microenvironment of PCNS-DLBCL and is correlated with increased TILs. PD-L1 and CD8⁺ and PD-1⁺ TILs have potential as prognostic biomarkers and therapeutic targets in PCNS-DLBCL.

Introduction

Primary diffuse large B-cell lymphoma of the central nervous system (PCNS-DLBCL) is an aggressive extranodal non-Hodgkin lymphoma that arises in immune-privileged sites. Although there is no consensus on the optimal treatment regimen for PCNS-DLBCL, high-dose methotrexate-based polychemotherapy with or without radiotherapy is widely used.¹ Rituximab as an initial treatment has been reported to be clinically beneficial.² However, PCNS-DLBCL has a higher rate of recurrence and a worse prognosis than systemic DLBCL despite the application of chemotherapeutic or radiotherapy; thus, novel therapeutic modalities are needed. Several clinical prognostic models including the International Extranodal Lymphoma Study Group (IELSG) score,³ the Nottingham–Barcelona score,⁴ and the Memorial Sloan–Kettering Cancer Center (MSKCC) class for PCNS-DLBCL have been developed.⁵ In addition, efforts have been made to identify pathologic or biological prognostic biomarkers; however, there are no robust prognostic models or biomarkers for PCNS-DLBCL.

Tumor cells use diverse strategies to render their microenvironment friendly to tumor progression and to evade host immune surveillance.⁶ The programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) pathway is an immune-checkpoint pathway utilized by tumor cells for immune escape. PD-1 is an inhibitory receptor expressed on activated T cells and other immune cells. PD-L1 is expressed on tumor cells and antigen-presenting cells and its expression is regulated by intrinsic (i.e., oncogenic signaling and PD-L1 gene alterations) as well as adaptive (i.e., interferon (IFN)-γ) produced by tumor-infiltrating immune cells) mechanisms. The binding of PD-L1 to PD-1 on activated T cells induces apoptosis, anergy, and functional exhaustion; in this way, tumor cells evade immune surveillance.⁷ PD-1/PD-L1 pathway blockades showed a considerable antitumor effect in patients with many solid tumors and those with refractory or relapsed Hodgkin and non-Hodgkin lymphomas.⁸ To date, the PD-1/PD-L1 pathway has been primarily investigated in systemic DLBCL. Several clinicopathological features including Epstein-Barr virus (EBV) infection,⁹
TILs tended to be significantly higher in tmPD-L1+ TILs \( (P = .092) \) and MYC negativity (raw \( P \leq .001 \)) \( (\rho = .036, P = .003 \) and \( \rho = .466, P = .007 \)). The number of CD8+ TILs and PD-1 expression were significantly positively correlated with the numbers of CD8+ TILs \( (\rho = .366, P = .044) \) and CD1+ TILs \( (P = .019) \) \( (\text{Figure 1(e)}) \). Moreover, after excluding the tPD-L1+ cases, tmPD-L1 expression was significantly positively correlated with the numbers of CD8+ TILs \( (\rho = .340, P = .007) \) and PD-1+ TILs \( (\rho = .366, P = .004) \) \( (\text{Supplementary Figure S1B-C}) \).

In the validation group \( (n = 42) \), 10 \( (23.8\%) \) and 13 \( (31\%) \) cases were tPD-L1+ and tmPD-L1+, respectively. Similar to the experimental group, a strong positive correlation between the numbers of CD8+ and PD-1+ TILs were observed \( (\rho = .874, P < .001) \) \( (\text{Supplementary Figure S2A}) \). The numbers of CD8+ TILs and PD-1+ TILs were significantly higher in tPD-L1+ cases compared to tPD-L1– cases \( (P = .010 \text{ and } .006) \), and in tmPD-L1+ cases compared to tmPD-L1– cases \( (P = .001 \text{ and } .001) \) \( (\text{Supplementary Figure S2B and C}) \). In the open datasets of mRNA expression of PCNSL tissues, CD274 (PD-L1) expression tended to be positively correlated with CD8A expression \( (\text{KAWAGUCHI dataset, Spearman's } \rho = .348, P = .044; \text{CHAPUY dataset, Spearman's } \rho = .54, P = .041; \text{CHANGOHK dataset, Spearman's } \rho = .75, P = .066) \) \( (\text{Supplementary Figure S3}) \).

### Relationships between PD-L1 expression and clinicopathological features

The overall clinicopathological features of the patients in the experimental and validation group are summarized in Table 1 and Supplementary Table S2, respectively. The relationships between PD-L1 expression and clinicopathological parameters are summarized in Figure 2 \( (\text{adjusted } P) \) and supplementary Figure S4 \( (\text{raw } P) \). A poor performance status \( (\text{ECOG 2–4}) \) tended to be associated with a high tPD-L1 level \( (\text{raw } P = .043; \text{adjusted } P = .092) \). Although the tPD-L1 levels were higher in tumors harboring wild-type \( CD79B \) \( (\text{raw } P = .049; \text{adjusted } P = .142) \), other pathological features–including age, cell-of-origin, \( MYD88 \) mutation, clinical prognostic models, and MYC/BCL2 expression–were not related to the tPD-L1 or tmPD-L1 level.

### Relationships between the number of CD8+ or PD-1+ TILs and clinicopathological features

The numbers of CD8+ TILs and PD-1+ TILs were not significantly different according to the steroid therapy status prior to the obtaining of tumor tissue \( (\text{Supplementary Figure S5}) \). The relationships between CD8+ and PD-1+ TILs and clinicopathological parameters are summarized in Figure 3 \( (\text{adjusted } P) \) and Supplementary Figure S6 \( (\text{raw } P) \). In contrast to PD-L1, the number of CD8+ TILs tended to be higher in patients with a good performance status \( (\text{ECOG 0–1}) \) \( (\text{raw } P = .046; \text{adjusted } P = .092) \), MYC negativity \( (\text{raw } P = .012; \text{adjusted } P = .048) \), and BCL2 negativity \( (\text{raw } P = .023; \text{adjusted } P = .092) \). The number of CD8+ TILs was lowest in MYC/BCL2 double expressers and highest in MYC/BCL2 non-expressers \( (\text{raw } P = .006; \text{adjusted } P = .024) \). The number of PD-1+ TILs also tended to be higher in patients with a good performance status and MYC or BCL2 negativity. In the validation group, the numbers of CD8+ and PD-1+ TILs were associated with clinicopathological
parameters in a pattern similar to that in the experimental group, but with reduced statistical significance (Supplementary Figure S7).

**PD-1 expression on PCNS-DLBCL tumor B cells**

Of the total patients, 16 (16/140, 11.4%) showed PD-1 expression on more than 50% of tumor B cells, mostly with moderate to strong intensity. These patients were characterized by favorable clinical features including the absence of deep-structure involvement ($P= .041$), unifocal disease ($P= .018$), and a lower Nottingham–Barcelona score ($P= .008$) (Supplementary Figure S8).

**Prognostic significance of PD-L1 expression and TILs**

The results of univariate analyses of survival according to clinicopathological parameters are summarized in
Supplementary Table S3. Old age and multifocal disease were associated with a worse prognosis (old age, PFS, P = .006 and OS, P < .001; multifocal disease, PFS, P = .034 and OS, P = .039). Patients with a high Nottingham–Barcelona score or MSKCC class had a poor prognosis (Nottingham–Barcelona score, PFS, P < .001; OS, P < .001; MSKCC class, PFS, P = .017; OS, P = .005). MYC and BCL2 double expressers showed shorter PFS (P = .036) and OS (P = .015). Patients treated with HD-MTX-based chemotherapy plus radiotherapy (59/98, 60.2%) showed a better PFS (P = .033) and OS (P = .008) than those treated with other regimens.

Kaplan-Meier survival analysis demonstrated that tPD-L1+ was significantly associated with a shorter OS (P = .026) and a tendency towards a shorter PFS (P = .088) (Figure 4a,b). tmPD-L1+ cases also tended to have a poor prognosis (Supplementary Figure S9A and B). Patients with large numbers of CD8+ or PD-1+ TILs had a longer OS (P = .081 and 0.044, respectively) (Figure 4c,d; Supplementary Figure S9C and D). tPD-L1+ patients with a small number of CD8+ or PD-1+ TILs showed the worst prognosis, and tPD-L1− patients with a large number of CD8+ or PD-1+ TILs the best prognosis; the difference in OS between these groups was significant (Figure 4e-h). In the low CD8+ or PD-1+ TILs group, tPD-L1+ patients tended to have worse PFS and OS than tPD-L1− patients. In the high PD-1− TIL group, tPD-L1+ patients had a worse OS than tPD-L1− patients (Figure 4h). Moreover, in tPD-L1− patients, a large number of PD-1+ TILs were significantly associated with a better prognosis (Figure 4h).

In a multivariate analysis, tPD-L1 expression and the number of PD-1+ TILs were found to be independent prognostic indicators for OS (tPD-L1+, P = .026, HR = 1.896 [95% CI, 1.081–3.325]; high PD-1− TILs, P = .004, HR = 0.428 [95% CI, 0.241–0.763]) (Table 2 and Supplementary Table S4).

In the validation group, tPD-L1 and tmPD-L1 had no prognostic significance (data not shown). However, a large number of CD8+ or PD-1+ TILs were significantly associated with a prolonged OS (CD8+ TILs, P = .003; PD-1+ TILs, P = .043) (Supplementary Figure S10A and B). In addition, tPD-L1− patients with a large number of CD8+ or PD-1− TILs had the longest OS (Supplementary Figure S10C and D).

Additionally, we evaluated “Immunoscore” using CD3+ TILs and CD8+ TILs, because immunoscore has been emerged as a good prognostic marker for cancer, especially for colon cancer.23–26 Consistent with previous studies on colon cancer, PCNS-DLBCL patients with high immunoscore showed significantly better OS than those with low immunoscore, when using the numbers of CD3+ and CD8+ TILs having minimum P value as cutoffs (P = .040) or using the median numbers of CD3+ and CD8+ TILs as cutoffs (P = .044) (Supplementary Figure S11).

Discussion

We investigated PD-L1 expression on tumor cells and in the tumor microenvironment, and CD8+ and PD-1+ TIL status in a large cohort of patients with PCNS-DLBCL. The results demonstrate that PD-L1 expression and CD8+ or PD-1+

---

**Table 1.** Clinicopathological characteristics of patients with PCNS-DLBCL.

| Variable | n (%) (total = 98) |
|----------|-------------------|
| **Age (years)** | Median, 61 (range, 10–82) |
| **Sex** | Male 56 (57.1) |
| **Female** | 42 (42.9) |
| **Initial symptoms** | Headache & vomiting 26 (26.5) |
| **Seizure** | 6 (6.1) |
| **ECOG PS** | 0, 1 61 (62.9) |
| **2–4** | 36 (37.1) |
| **≥ 70** | 83 (86.5) |
| **< 70** | 13 (13.5) |
| **B Symptoms** | Absent 94 (65.9) |
| **Present** | 4 (4.1) |
| **Serum LDH** | Normal 58 (61.7) |
| **Elevated** | 36 (38.3) |
| **EBV** | Negative 25 (26.7) |
| **Positive** | 2 (7.4) |
| **Cell-of-origin** | GCB 23 (23.5) |
| **Non-GCB** | 75 (76.5) |
| **Involvement of deep structures** | Absent 29 (29.6) |
| **Present** | 69 (70.4) |
| **Extent of disease** | Unifocal 39 (39.8) |
| **Multifocal** | 59 (60.2) |
| **Ocular involvement** | Absent 87 (89.7) |
| **Present** | 10 (10.3) |
| **CSF protein** | Normal 33 (34.0) |
| **Elevated** | 48 (59.3) |
| **CSF cytology** | Negative 72 (85.7) |
| **Positive** | 12 (14.3) |
| **IELSG** | 0–1 12 (15.0) |
| **2–3** | 51 (63.8) |
| **4–5** | 17 (21.3) |
| **Nottingham-Barcelona** | 0–1 48 (49.5) |
| **2–3** | 49 (50.5) |
| **MSKCC class** | 1 18 (18.6) |
| **2** | 68 (70.1) |
| **3** | 11 (11.3) |
| **Prior steroid therapy** | None 77 (79.8) |
| **≤ 1 day** | 7 (7.1) |
| **> 1 day, ≤ 3 days** | 10 (10.2) |
| **unknown** | 4 (4.1) |
| **Radiotherapy** | Not done 36 (31.6) |
| **Done** | 78 (68.4) |
| **Chemotherapy** | MVP 79 (81.4) |
| **HD-MTX** | 14 (14.4) |
| **Others** | 4 (4.1) |
| **Rituximab** | Not done 103 (90.4) |
| **Done** | 11 (9.6) |
| **IT-MTX** | Not done 89 (78.1) |
| **Done** | 25 (21.9) |
| **Biopsy** | Subtotal resection 74 (75.5) |
| **Gross total resection** | 16 (16.3) |
| **MYC expression** | < 40 78 (79.6) |
| **≥ 40** | 20 (20.4) |
| **BCL2 expression** | < 60 41 (41.8) |
| **≥ 60** | 57 (58.2) |
| **MYC/BCL2 expression** | Others 82 (83.7) |
| **MYD88 mutation** | Double expresser 16 (16.3) |
| **Wild-type** | 49 (46.5) |
| **Mutation** | 27 (25.5) |
| **CD79B mutation** | Wild-type 71 (77.2) |
| **Mutation** | 21 (22.8) |

Abbreviations: CSF, cerebrospinal fluid; ECOG PS, Eastern Cooperative Oncology Group Performance GCB, germinal center B cell-like; HD-MTX, high-dose methotrexate; IELSG, International Extranodal Lymphoma Study Group; IT-MTX, intrathecal methotrexate; KPS, Karnofsky Performance Status score; LDH, lactate dehydrogenase; MSKCC, Memorial Sloan Kettering Cancer Center; MVP, chemotherapy regimen comprising high-dose methotrexate, vincristine, and procarbazine.

*Some cases had missing values.

*Cell-of-origin was determined by Hans algorithm (Blood 2004;103:275–82).

*Deep structures are the periventricular regions, basal ganglia, brain stem, and/or cerebellum.

*Including eight patients who received rituximab-MVP.

*Others include COPADM and CHOP.
TILs are correlated with each other and associated with several clinicopathological parameters. Moreover, high tumoral PD-L1 expression and few CD8+ or PD-1+ TILs on patients with PCNS-DLBCL were predictive of a poor prognosis.

In this study, a substantial proportion of PCNS-DLBCL tumor and/or non-tumor cells expressed PD-L1. Notably, the numbers of CD8+ and PD-1+ TILs were positively correlated with tumoral and/or non-tumoral PD-L1 expression and significantly correlated with the expression of tmPD-L1 rather than tPD-L1. Moreover, after the exclusion of tPD-L1+ patients, significant positive correlations between the tmPD-L1 expression level and the numbers of CD8+ and PD-1+ TILs were observed. A positive correlation between PD-L1 and CD8 in tumor and tumor microenvironment of PCNSL was also validated at the mRNA level using a publicly available database. PD-L1 expression on tumor cells is induced by extrinsic ways, such as cytokines, primarily IFN-γ, secreted by activated immune (especially T) cells; and by intrinsic ways. An increased PD-L1 gene copy number was reported to contribute to tPD-L1 expression in a substantial portion of PCNS-DLBCL patients. In contrast, PD-L1 expression on non-tumor cells (e.g., macrophages) is induced by cytokines secreted from surrounding immune cells. Therefore, the stronger positive correlation between tmPD-L1+ compared to tPD-L1+ cases with the number of TILs, particularly PD-1+ TILs (putatively T-cell signaling-activated T cells), suggests that adaptive induction of PD-L1 expression in non-tumor cells, as well as adaptive and intrinsic induction of PD-L1 expression in tumor cells, plays a role in immune evasion by PCNS-DLBCL.

In systemic DLBCL, tumoral PD-L1 expression is related to EBV infection and a non-GCB phenotype. In this study, PD-L1 expression in PCNS-DLBCL tended to be higher in patients who were older, and in those with a poor performance status, and wild-type CD79B, but was not associated with the cell-of-origin. These differences might be attributable to the pathological and genetic features of PCNS-DLBCL, which are distinct from those of systemic DLBCL, e.g., higher rates of non-GCB phenotype, 9p24.1 copy number gain, and MYD88 mutation, and lower rates of EBV infection. In contrast to PD-L1 expression, an increased number of CD8+ or PD-1+ TILs was associated with favorable clinicopathological features, such as good performance status and MYC and/or BCL2 negativity. Because a large number of CD8+ or PD-1+ TILs imply an active immune response in the tumor microenvironment, such an association is reasonable. The small number of TILs in MYC/BCL2 double expressers is intriguing, as it suggests a link between the poor prognostic implications of MYC/BCL2 double expression with the immune microenvironment of systemic and PCNS-DLBCL.
PD-1 expression is induced by T-cell receptor signaling on activated T cells, and PD-1 expression was mostly observed on activated T cells in the DLBCL microenvironment. However, PD-1 is expressed on malignant B cells in 2–22% of systemic DLBCL cases, but the clinical relevance of this is unclear. In this study, PD-1 was expressed on malignant B cells in 11% of patients with PCNS-DLBCL. Moreover, tumoral PD-1 expression was significantly associated with several favorable clinical features including the absence of deep-structure involvement, unifocal disease, and a low Nottingham–Barcelona score. It was reported that PD-1 functions as a tumor suppressor in T-cell lymphoma by suppressing oncogenic T-cell signaling. Moreover, PD-1 is upregulated in activated human B cells and inhibits B-cell activation upon binding to PD-L1. Taken together, the findings of this study suggest that PD-1 expressed on malignant B cells could play a tumor-suppressive role in B-cell lymphoma. Larger clinical and functional studies are needed to evaluate the prognostic significance and biological role of PD-1 expression on malignant B cells.

The prognostic implications of PD-L1 expression and PD-1+ TILs in PCNS-DLBCL are disputed. In previous studies of PCNS-DLBCL, high PD-L1 expression was unrelated, or related to a favorable prognosis, an increased PD-1+ TILs were related to an unfavorable prognosis. This study included the largest population of any similar work to date, analyzed the prognostic implications in experimental and validation groups and according to treatment modality, involved a multivariate analysis, quantified PD-L1 expression and enumerated TILs, and evaluated PD-L1 expression together with CD8+ or PD-1+ TILs. We found that tumoral PD-L1 expression was an independent prognostic indicator of a poor OS. However, tmPD-L1 expression was not significantly related to the prognosis in patients with PCNS-DLBCL. These findings are comparable to those reported in patients with systemic DLBCL in that non-tumoral PD-L1 expression was not significantly correlated with the clinical outcome. PD-L1 on tumor cells or immune cells contributes to immune escape, but the relative contributions of PD-L1 expression on these cells are context-dependent. Thus, the prognostic implications of PD-L1 expression on tumor cells versus immune cells may differ among cancer types. Meanwhile, the lack of prognostic significance of PD-L1 in the validation group may be attributable to the small number of cases in this group and/or other confounding factors, such as differences in treatment modalities. In previous studies, high level of soluble PD-L1 in blood was an independent poor prognostic factor for OS in patients with systemic DLBCL. Given the poor
prognostic implication of tPD-L1 in PCNS-DLBCL observed in this study, it may deserve to investigate the prognostic significance of soluble PD-L1 in blood or cerebrospinal fluid in PCNS-DLBCL. A large number of CD8$^+$ or PD-1$^+$ TILs were associated with prolonged OS and the latter was an independent prognostic factor for OS. The prognostic implications of CD8$^+$ or PD-1$^+$ TILs were confirmed in the validation group. These findings suggest that the presence of large numbers of TILs, particularly PD-1$^+$ TILs, reflects an active immune response in the tumor microenvironment and is thus related to a favorable clinical outcome of PCNS-DLBCL. The binding

Figure 4. Prognostic significance of tPD-L1, CD8$^+$ TILs, and PD-1$^+$ TILs. Kaplan-Meier analysis of PFS and/or OS according to tPD-L1 (tPD-L1-, n = 63; tPD-L1+, n = 35) (a-b), CD8$^+$ TILs (Low CD8$^+$ TILs, n = 42; High CD8$^+$ TILs, n = 54) (c), PD-1$^+$ TILs (Low PD-1$^+$ TILs, n = 44; High PD-1$^+$ TILs, n = 46) (d), tPD-L1 plus CD8$^+$ TILs (tPD-L1-/Low CD8$^+$ TILs, n = 27; tPD-L1+/High CD8$^+$ TILs, n = 34; tPD-L1+/Low CD8$^+$ TILs, n = 15; tPD-L1-/High CD8$^+$ TILs, n = 20) (e-f), and tPD-L1 plus PD-1$^+$ TILs (tPD-L1+/Low PD-1$^+$ TILs, n = 31; tPD-L1-/High PD-1$^+$ TILs, n = 29; tPD-L1+/Low PD-1$^+$ TILs, n = 13; tPD-L1+/High PD-1$^+$ TILs, n = 17) (g-h). Differences in survival were analyzed by log-rank test. † P = .05–.1, *P < .05.

Table 2. Multivariate analysis of overall survival (OS) in patients with PCNS-DLBCL.

| HR (95% CI) | P  |
|-------------|----|
| Age         | 1.045 (1.013–1.077) | 0.005 |
| N-B score 2–3 | 1.977 (1.042–3.750) | 0.037 |
| MSKCC class | - | - |
| HD-MTX+RTx  | 0.582 (0.333–1.018) | 0.058 |
| MYC/BCL2 DE | - | - |
| tPD-L1+     | 1.896 (1.081–3.325) | 0.026 |
| High CD8$^+$ TILs | 0.428 (0.241–0.763) | 0.004 |
| High PD-1$^+$ TILs | - | - |

Abbreviations: CI, confidence interval; DE, double expresser; HD-MTX, high-dose methotrexate; MSKCC, Memorial Sloan Kettering Cancer Center; N-B, Nottingham–Barcelona; RTx, radiotherapy.

prognostic implication of tPD-L1 in PCNS-DLBCL observed in this study, it may deserve to investigate the prognostic significance of soluble PD-L1 in blood or cerebrospinal fluid in PCNS-DLBCL. A large number of CD8$^+$ or PD-1$^+$ TILs were associated with prolonged OS and the latter was an independent prognostic factor for OS. The prognostic implications of CD8$^+$ or PD-1$^+$ TILs were confirmed in the validation group. These findings suggest that the presence of large numbers of TILs, particularly PD-1$^+$ TILs, reflects an active immune response in the tumor microenvironment and is thus related to a favorable clinical outcome of PCNS-DLBCL.
of PD-L1 to PD-1 transmits an inhibitory signal to activated T cells; therefore, we analyzed survival according to PD-L1 and TIL status. tPD-L1+ patients with few TILs showed the worst prognosis, whereas tPD-L1− patients with a large number of TILs showed the best prognosis. tPD-L1+ status with low TIL infiltration is regarded as intrinsic induction of PD-L1. The worse prognosis of these cases suggests that PD-L1 plays an intrinsic role in tumor progression other than dampening T-cell-mediated immune responses. Alternatively, factors that upregulate the expression of PD-L1, such as chromosome 9p alterations and oncogenic signaling, may contribute to tumor progression. Among the cases with a large number of PD-1+ TILs, tPD-L1+ cases had a shorter OS than tPD-L1− cases. These data suggest that the expression of PD-L1 on tumor cells impairs anti-tumor T-cell responses, leading to a poor clinical outcome.

Different organs have different immune microenvironments. Immune-cell infiltrates are reported to be less marked in PCNS-DLBCL compared to systemic DLBCL, which may partly explain the poor prognosis of PCNS-DLBCL. We report here that PCNS-DLBCL has substantial immune-cell infiltration, and that PD-L1 expression and TILs are related and have prognostic implications. Moreover, we observed that immunoscore based on CD3 and CD8+ TILs was associated with a favorable prognosis of patients with PCNS-DLBCL, similar to colon cancer. These findings further suggest that tumor immune microenvironment may be important for the pathobiology of PCNS-DLBCL and the PD-1/PD-L1 pathway contributes to immune evasion by PCNS-DLBCL, even in immune-privileged sites. Consistently, four patients with relapsed/refractory PCNS-DLBCL showed objective responses to PD-1 blockade; three patients exhibited a complete response. A clinical trial aiming to confirm the efficacy of PD-1 blockade in PCNS-DLBCL is ongoing (CA209-647, #NCT02857426).

This study has several limitations. First, the discriminative power of the statistical analysis of some of the variables was limited by the sample size. Second, the retrospective nature of this study resulted in disparities in the treatment and follow-up protocols. Third, genetic factors that affect PD-L1 expression, such as 9p24.1/ PD-L1 gene alteration, were not evaluated. Fourth, we addressed PD-L1 expression mainly in tumoral and non-tumoral cells, not discriminating various immune cells with a potential to express PD-L1 within the tumor microenvironment.

In summary, our data demonstrate that PD-L1 expression in the PCNS-DLBCL tumor microenvironment is positively correlated with infiltration of CD8+ or PD-1+ TILs, that tumoral PD-L1 expression is associated with a poor prognosis, and that a large number of CD8+ or PD-1+ TILs are associated with a good prognosis. These findings suggest that PD-L1-mediated immune evasion is important for tumor progression in PCNS-DLBCL. Therefore, PD-L1 expression and CD8+ and PD-1+ TIL status have potential as prognostic biomarkers and therapeutic targets.

**Materials and methods**

**Patients**
Two cohorts of patients with PCNS-DLBCL were included in this study. The experimental group consisted of 98 patients diagnosed and managed at Seoul National University Hospital (SNUH, Seoul, Republic of Korea) from 2000 to 2012. The validation group consisted of 42 patients treated homogeneously with R-MVP (rituximab and chemotherapy with high-dose methotrexate, vincristine, and procarbazine) at SNUH from 2013 to 2015. The patients’ diagnoses were confirmed according to the current World Health Organization classification. Patients treated with steroid therapy 4 or more days prior to the obtaining of tumor tissues were excluded. Clinical data were retrieved by hematologists. This study followed the recommendations of the World Medical Association Declaration of Helsinki and was approved by the Institutional Review Board of SNUH (No. 1609–129-795).

**Immunohistochemistry (IHC)**
Immunohistochemical staining was performed using whole formalin-fixed paraffin-embedded tissue sections and antibodies against PD-L1 (clone E1L3N, Cell Signaling Technology, Danvers, MA, USA), CD3 (clone 2GV6, Ventana Medical Systems, Tucson, AZ, USA), CD8 (clone SP16, Thermo Fischer Scientific, Rockford, IL, USA), PD-1 (clone MRQ-22), MYC (clone EP121) (Cell Marque, Rocklin, CA, USA), BCL2 (clone 124, DAKO, Carpinteria, CA, USA), CD10 (clone 56C6), BCL6 (clone LN22), and MUM1 (clone Ma695) (Novocasta, Newcastle, UK). Staining was performed using a Ventana Benchmark XT (Ventana Medical Systems) or a Bond-Max autostainer (Leica Microsystems, Melbourne, Australia).

**Interpretation of PD-L1 IHC and quantification of CD8+ and PD-1+ TILs**
PD-L1 expression was evaluated based on the intensity of membrane staining and the proportion (or level) of immunostained cells. PD-L1 expression on tumor cells was designated tPD-L1, and PD-L1 expression on both tumor and non-tumor cells (primarily macrophages) was designated tmPD-L1. PD-L1 staining of any intensity of ≥30% of total tumor cells was defined as tPD-L1-positive, and PD-L1 staining of any intensity of ≥30% of total cellularity including tumor cells and non-tumoral cells in the microenvironment was considered as tmPD-L1-positive.

CD8+ and PD-1+ TILs were enumerated as detailed in the Supplementary Methods, and the numbers of TILs per unit area (mm²) were calculated. For dichotomization of cases, the cutoff values with the greatest discriminatory power were determined by receiver operating characteristic curve analysis and log-rank test. Briefly, in the experimental group, CD8+ and PD-1+ TILs were manually counted in all tumor areas of biopsied samples and in representative tumor areas of resected samples. Cutoff values of 542.6/mm² for CD8+ and 18.8/mm² for PD-1+ TILs were used to classify the cases into the CD8+ and PD-1+ TIL-low and -high groups, respectively. In the validation group, CD8+ and PD-1+ TILs in all tumor areas were enumerated using ImageScope software (Aperio Technologies, Alta Vista, CA, USA). Cutoff values of 760/mm² for CD8+ and 174.4/mm² for PD-1+ TILs were adopted.
Assessment of immunoscore

Immunoscore was evaluated in 64 cases of the experimental group. Because there was no solid guideline for scoring the immunoscore of lymphoma, we made some modifications from previous studies of colon cancer.23–25 Mostly, lymphoma tissue is taken by biopsy, so evaluating TILs from the invasive margin is frequently limited. Therefore, we only evaluated the infiltration of CD3⁺ and CD8⁺ TILs from tumor center (cells per mm²) and dichotomized the cases into high and low TIL infiltration according to an optimal cutoff value determined using the minimum P value approach and median. Cases are stratified according to a score range from 0 to 12, depending on the sum of high TIL infiltration observed.

Sanger sequencing

The mutation status of MYD88 and CD79B was examined by Sanger sequencing (detailed in Supplementary Methods).

Open database validation

For external validation, three publicly available datasets of RNA expressions of PCNSL were used (detailed in Supplementary Methods).

Statistical analyses

All statistical analyses were conducted using SPSS software (v. 21; IBM Corp., Armonk, NY, USA) and MedCalc software (v. 18.5; MedCalc Software, Ostend, Belgium). Graphs were created using Prism software (v. 5; GraphPad Software, La Jolla, CA, USA). Correlation analysis or comparison between PD-L1 expression, TILs, and clinicopathological parameters were performed using the Mann–Whitney U test, Spearman correlation analysis, and Kruskal–Wallis test. Multiple test correction was done by Benjamini and Hochberg method. The cutoff values of PD-L1, CD8⁺ TILs, PD-1⁺ TILs, MYC, and BCL2 were determined by receiver operating characteristic (ROC) curve analysis and log-rank test. Overall survival (OS) was measured from the date of diagnosis to the date of death or the last follow-up. Progression-free survival (PFS) was calculated from the date of chemotherapy initiation to the date of disease progression, death, or the last follow-up. PFS and OS were analyzed using the Kaplan-Meier method and the log-rank test. Univariate and multivariate analyses were performed by Cox regression. Two-sided P-values <0.05 were considered indicative of statistical significance.

Acknowledgments

This work was supported by the Basic Science Research Program (grant No.: NRF-2016R1D1A1B01015964) through the National Research Foundation (NRF) funded by the Ministry of Education, Science and Technology (MEST), Republic of Korea.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Funding

This work was supported by the Ministry of Education, Science and Technology [NRF-2016R1D1A1B01015964].

ORCID

Dohee Kwon http://orcid.org/0000-0002-4725-3852

References

1. Grommes C, DeAngelis LM. Primary CNS Lymphoma. J Clin Oncol. 2017;35:2410–2418. doi:10.1200/JCO.2017.72.7802.
2. Ferreri AJ, Cwynarski K, Pulecynski E, Ponsoni M, Deckert M, Politi LS, Torri V, Fox CP, Rose PI, Scherb E, et al. Chemoinmunotherapy with methotrexate, cytarabine, thiopeta, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol. 2016;3:e217–e227. doi:10.1016/S2352-3026(16)30036-3.
3. Ferreri AJ, Blay JY, Reni M, Pasini F, Spina M, Ambrosi M, Calderoni A, Rossi A, Vavassori V, Conconi A, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol. 2003;21:266–272. doi:10.1200/JCO.2003.09.139.
4. Bessell EM, Graus F, Lopez-Guillermo A, Lewis SA, Villa S, Verger E, Petit J. Primary non-Hodgkin’s lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors. Int J Radiat Oncol Biol Phys. 2004;59:501–508. doi:10.1016/j.ijrobp.2003.11.001.
5. Abbey LE, Ben-Porat L, Panageas KS, Yahalom J, Berkey B, Curran W, Schultz C, Leibel S, Nelson D, Mehta M, et al. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol. 2006;24:5711–5715. doi:10.1200/JCO.2006.08.2941.
6. Finn OJ. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol. 2012;23(Suppl 8):viii6–9. doi:10.1093/annonc/mds256.
7. Topalian SL, Drake CG, Pardoll DM. Immune-checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27:450–461. doi:10.1016/j.ccell.2015.03.001.
8. Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol. 2007;19:813–824. doi:10.1093/intimm/dxm057.
9. Merrymann RW, Armand P, Wright KT, Rodig SJ. Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma. Blood Adv. 2017;1:2643–2654. doi:10.1182/bloodadvances.2017012534.
10. Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MG, Xu ML, Yu H, Fletcher CD, Freeman GJ, Shipp MA, et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res. 2013;19:3462–3473. doi:10.1158/1078-0432.CCR-13-0855.
11. Georgiou K, Chen L, Berglund M, Ren W, de Miranda NF, Lisboa S, Fangazio M, Zhu S, Hou Y, Wu K, et al. Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas. Blood. 2016;127:3026–3034. doi:10.1182/blood-2015-12-686550.
12. Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, Gownmell E, Chapuy B, Takeyama K, Neuberg D, Golub TR, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosis Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116:3268–3277. doi:10.1182/blood-2010-05-282780.
13. Andorsky DJ, Yamada RE, Said J, Pinkus GS, Betting DJ, Timmerman JM. Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of...
21. Cho H, Kim SH, Kim SJ, Chang JH, Yang WI, Suh CO, Kim YR, Jung JE, Cheong JW, Min YH, et al. Programmed cell death 1 expression is associated with inferior survival in patients with primary central nervous system lymphomas. Oncotarget. 2015;6:78371–78328. doi:10.18632/oncotarget.20264.

22. Hayano A, Komohara Y, Takashima Y, Takeya H, Homma J, Fukai J, Iwadate Y, Kajiwara K, Ishizawa S, Hondoh H, et al. Programmed cell death ligand 1 expression in primary central nervous system lymphomas: a clinicopathological study. Anticancer Res. 2017;37:5655–5666. doi:10.21873/anticancer.12001.

23. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, et al. Type, density, and location of immune cells within human colorectal tumours predict clinical outcome. Science. 2006;313:1960–1964. doi:10.1126/science.1129139.

24. Anitei MG, Zeitoun G, Mlecnik B, Mariot F, Haiech N, Todosi AM, Kirilovsky A, Lacerge C, Binede G, Ferarui D, et al. Prognostic and predictive values of the immunoscore in patients with rectal cancer. Clin Cancer Res. 2014;20:1891–1899. doi:10.1158/1078-0432.CCR-13-2830.

25. Yomoda T, Sudo T, Kawahara A, Ishigaki T, Shimomura S, Tajiri K, Nagasu S, Fujita F, Kinugasa T, Akagi Y. The immunoscore—A superior prognostic tool in stages II and III colorectal cancer and is significantly correlated with programmed death-ligand 1 (PD-L1) expression on tumor-infiltrating mononuclear cells. Ann Surg Oncol. 2019;26:415–424. doi:10.1245/s10434-018-7710-z.

26. Pages F, Mlecnik B, Mariot F, Binede G, Ou FS, Bifulco C, Lugli A, Zlobec I, Rau TT, Berger MD, et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018;391:2128–2139. doi:10.1016/S0140-6736(18)30789-X.

27. Kim S, Nam SJ, Kwon D, Kim H, Lee E, Kim TM, Heo DS, Park SH, Kim CW, Jeon YK. MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system. BMC Cancer. 2016;16:363. doi:10.1186/s12885-016-2397-8.

28. Laurent C, Charmy K, Gravier P, Tosolini M, Franchet C, Ysebaert L, Brouset P, Bidaut A, Ycart B, Fournier J. Several immune escape patterns in non-Hodgkin’s lymphomas. Oncoimmunology. 2015;4:e1026530. doi:10.18632/oncotarget.2017-1008371.

29. Muenst S, Hoeller S, Willi N, Dirnhofer S, Tzankov A. Diagnostic and prognostic utility of PD-L1 in B cell lymphomas. Dis Markers. 2010;29:47–53. doi:10.3233/DMA-2010-0725.

30. Xerri L, Chetelatte B, Serriari N, Attias C, Guillaume Y, Arnoulet C, Olive D. Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia. Hum Pathol. 2008;39:1050–1058. doi:10.1016/j.humpath.2007.11.012.

31. Wartewig T, Kurygis K, Keppler S, Pechloff K, Hameister E, Ollinger R, Maresch R, Buch T, Steiger K, Winter C, et al. PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis. Nature. 2017;552:121–125. doi:10.1038/nature24649.

32. Thibult ML, Mamesier E, Gartner-Dardenne J, Pastor S, Just-Landi S, Xerri L, Chetelatte B, Olive D. PD-L1 is a novel regulator of human B-cell activation. Int Immunol. 2013;25:129–137. doi:10.1093/immunol/dxt098.

33. Okazaki T, Maeda A, Nishimura H, Kurosaki T, Honjo T. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci U S A. 2001;98:13866–13871. doi:10.1073/pnas.214865908.

34. Lau J, Cheung J, Navarro A, Lianoglou S, Haley B, Topkal P, Sanders L, Koeppen H, Caplazi P, McBride J, et al. Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice. Nat Commun. 2017;8:14572. doi:10.1038/ncomms14572.

35. Juneja VR, McGuire KA, Manguo RT, LaFleur MW, Collins N, Haining WN, Freeman GI, Sharpe AH. PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. J Exp Med. 2017;214:895–904. doi:10.1084/jem.20160801.

36. Rossille D, Azaoui I, Feldman AL, Maurer MI, Labouré G, Parrens M, Pantages C, Habermann TM, Ansell SM, Link BK, et al. Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients. Leukemia. 2017;31:998–991. doi:10.1038/leu.2016.385.

37. Teng MW, Ngiov SF, Ribas A, Smyth MJ. Classifying Cancers Based on T-cell Infiltration and PD-L1. Cancer Res. 2015;75:2139–2145. doi:10.1158/0008-5472.CAN-15-0255.

38. Chang C, Lin CH, Cheng AL, Medeiros LJ, Chang KC. Primary central nervous system lymphomas: a diagnostic study to identify a subset of primary central nervous system diffuse large B-cell lymphoma with poorer immune cell infiltration and prognosis than its peripheral counterpart. Histopathology. 2015;67:625–635. doi:10.1111/his.12706.

39. Nam SJ, Kim S, Kwon D, Kim H, Kim S, Lee E, Kim TM, Heo DS, Park SH, Lim MS, et al. Prognostic implications of tumor-infiltrating macrophages. M2 macrophages, regulatory T-cells, and indoleamine 2,3-dioxgenase-positive cells in primary diffuse large-B-cell lymphoma of the central nervous system. Oncoimmunology. 2018;7:e1442164. doi:10.1080/2162402X.2018-1490854.

40. Nayak L, Iwamoto FM, LaCasce A, Mukundan S, Roemer MGM, Chappuy B, Ar mand P, Rodig SJ, Shipp MA. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. Blood. 2017;129:3071–3073. doi:10.1182/blood-2017-01-764209.